share_log

藥明合聯:2024中期報告

WUXI XDC: Interim Report 2024

HKEX ·  Sep 26 05:18

Summary by Moomoo AI

藥明合聯生物技術有限公司(WUXI XDC)於2024年6月30日公布其半年度財務報告。報告顯示,公司在截至2024年6月30日的六個月內,收益達到人民幣1,665.2百萬元,同比增長67.6%;毛利為人民幣535.3百萬元,同比增長133.4%。公司擁有人應佔純利為人民幣488.2百萬元,同比大幅增長175.5%。此外,公司擁有人應佔經調整純利(非國際財務報告準則指標)為人民幣533.6百萬元,同比增長146.6%。公司於2023年11月成功完成全球發售並於聯交所主板上市,集資總額逾40億港元。董事會不建議就截至2024年6月30日止六個月派付任何中期股息。
藥明合聯生物技術有限公司(WUXI XDC)於2024年6月30日公布其半年度財務報告。報告顯示,公司在截至2024年6月30日的六個月內,收益達到人民幣1,665.2百萬元,同比增長67.6%;毛利為人民幣535.3百萬元,同比增長133.4%。公司擁有人應佔純利為人民幣488.2百萬元,同比大幅增長175.5%。此外,公司擁有人應佔經調整純利(非國際財務報告準則指標)為人民幣533.6百萬元,同比增長146.6%。公司於2023年11月成功完成全球發售並於聯交所主板上市,集資總額逾40億港元。董事會不建議就截至2024年6月30日止六個月派付任何中期股息。
Wuxi XDC, a subsidiary of WuXi AppTec, announced its semi-annual financial report on June 30, 2024. The report shows that in the six months ending on June 30, 2024, the company's revenue reached 1,665.2 million yuan, a year-on-year increase of 67.6%; gross profit was 535.3 million yuan, a year-on-year increase of 133.4%. The net profit attributable to owners of the company was 488.2 million yuan, a significant increase of 175.5% year-on-year. In addition, the adjusted net profit attributable to owners (non-IFRS indicators) was 533.6 million yuan, an increase of 146.6% year-on-year. The company successfully completed a global offering in November 2023 and listed on the Main Board of the Hong Kong Stock Exchange, raising over 4 billion Hong Kong dollars. The board of directors does not recommend paying any interim dividends for the six months ending on June 30, 2024.
Wuxi XDC, a subsidiary of WuXi AppTec, announced its semi-annual financial report on June 30, 2024. The report shows that in the six months ending on June 30, 2024, the company's revenue reached 1,665.2 million yuan, a year-on-year increase of 67.6%; gross profit was 535.3 million yuan, a year-on-year increase of 133.4%. The net profit attributable to owners of the company was 488.2 million yuan, a significant increase of 175.5% year-on-year. In addition, the adjusted net profit attributable to owners (non-IFRS indicators) was 533.6 million yuan, an increase of 146.6% year-on-year. The company successfully completed a global offering in November 2023 and listed on the Main Board of the Hong Kong Stock Exchange, raising over 4 billion Hong Kong dollars. The board of directors does not recommend paying any interim dividends for the six months ending on June 30, 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more